Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0995 • ACR Convergence 2021
Innate Immune Tolerance Attenuates Zymosan-Induced Arthritis, Inflammatory Gene Expression and Synovial Neutrophil Infiltration
Richard Bell, Chao Yang, Caroline Brauner, Upneet Sohki, Rouxi Yuan, Bikash Mishra, Mahesh Bachu and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY
Background/Purpose: Zymosan (Zym) induces arthritis through TLR2- and Dectin-1-activated NK-κB signaling and inflammatory myeloid cell infiltration into the synovium of the injected joint. Innate immune…
Abstract Number: 1074 • ACR Convergence 2021
Satisfaction with a Virtual Learning Collaborative Aimed at Implementing Treat to Target (TTT) in Rheumatoid Arthritis (RA)
Jack Ellrodt¹, Josef Smolen², Theodore Pincus³, Nancy Shadick¹, Jeffrey Katz¹, Leah Santacroce¹, Jacklyn Stratton¹, DH Solomon¹, Prem Chatpar⁴, Mary Stocks⁴, Breanna Mundell⁴, Christina Downey⁵, Karina Torralba⁶, Douglas White⁷, Meggan Baudek⁷, Steven Szlembarski⁷, Sharon Barnhart⁷, Jawad Bilal⁸, Albert Redford⁸, Dylan Lee⁸, Julia Buchfuhrer⁹, Helene Kramer⁸, C. Kent Kwoh¹⁰, Michel Villatoro-Villar⁸, Asha Patnaik¹¹, Edgardo Guzman¹¹, Rebecca Trachtman¹², John Tesser¹³, Dijana Music¹⁴, Lexi Mickey¹⁵, Mona Amin¹⁶, Jeffrey Potter¹⁷, Joshua Sundhar¹⁸, Jessica Sheingold¹⁹, Juan Schmukler²⁰, Diane Horowitz²¹, Hannah Gulko²¹, Robert Quinet²², Swathi Dhulipala²³, Ronak Patel²⁴, Chandana Keshavamurthy²⁵, Guiset Carvajal²⁶, Rhonda Dunn²⁷, Bharat Kumar²⁷, Aleksander Lenert²⁷, Hanna Zembrzuska²⁷, Matthew Gebre²⁸, Petar Lenert²⁹, Allen Anandarjah³⁰, Annie Yang³⁰, Linda Grinnell-Merrick³⁰, Shadefai Goldsmith³⁰, Jonna Zelie³⁰, Leanna Wise³¹, Nicole Zagelbaum Ward³² and Jeffrey Kaine³³, ¹Brigham and Women's Hospital, Boston, MA, ²University of Vienna, Vienna, Austria, ³Rush University Medical Center, Chicago, IL, ⁴Dr. Chatpar and Associates, LLC, Plainview, NY, ⁵Loma Linda University Medical Center, Redlands, CA, ⁶Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, ⁷Gundersen Health, La Crosse, WI, ⁸University of Arizona, Phoenix, AZ, ⁹University of Arizona, Pheonix, AZ, ¹⁰University of Arizona College of Medicine, Tuscon, AZ, ¹¹Stony Brook School of Medicine, Stony Brook, NY, ¹²Icahn School of Medicine at Mount Sinai, New York, NY, ¹³Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ¹⁴Arizona Arthritis and Rheumatology Associates, Glendale, AZ, ¹⁵Arthritis and Rheumatology Associates- Glendale, Glendale, AZ, ¹⁶Arthritis and Rheumatology Associates- Phoenix, Phoenix, AZ, ¹⁷Arthritis & Rheumatism Associates, Wheaton, MD, ¹⁸Arthritis Rheum & Back Disease Assoc., Voorhees, NJ, ¹⁹MedStar Georgetown University Hospital, Washington, DC, ²⁰Mount Sinai- Chicago, Chicago, IL, ²¹Northwell Health, Great Neck, NY, ²²Ochsner Health, River Ridge, LA, ²³Ochsner Clinic Foundation, River Ridge, LA, ²⁴Ochsner Health, Jefferson, LA, ²⁵Ochsner, New Orleans, LA, ²⁶University of Colorado, Colorado, CO, ²⁷University of Iowa, Iowa City, IA, ²⁸Loma Linda University Medical Center, Loma Linda, CA, ²⁹University of Iowa Medical School, Iowa City, IA, ³⁰University of Rochester, Rochester, NY, ³¹LAC+USC/Keck Medicine of USC, Pasadena, CA, ³²LAC+USC Medical Center, Los Angeles, CA, ³³Cullowhee, NC
Background/Purpose: Learning collaboratives (LC) have been used widely for quality improvement in healthcare, and a recent 9-month in person LC was found effective for improving…
Abstract Number: 1201 • ACR Convergence 2021
Younger Age and Smoking Status Are Associated with Delayed Diagnosis of Rheumatoid Arthritis in a U.S. Veteran Population
Steven Taylor¹, Bryant England², Joshua Baker³, Brian Sauer⁴ and John Richards⁵, ¹UPMC, Pittsburgh, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah, Salt Lake City, UT, ⁵Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA
Background/Purpose: RA is a complex multisystem disease, which, untreated, results in debilitating joint damage, excess morbidity, and premature mortality. Previous research has demonstrated an association…
Abstract Number: 1217 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Mohammad Movahedi¹, Denis Choquette², Louis Coupal², Angela Cesta³, Xiuying Li³, Edward Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁴Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease-…
Abstract Number: 1233 • ACR Convergence 2021
Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Edward Keystone³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ³Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as an alternative option to biologic disease modifying antirheumatic drugs…
Abstract Number: 1249 • ACR Convergence 2021
In Rheumatoid Arthritis, Inhibition of the Lactate Monocarboxylate Transporters-1, and -4 in Pathological Fibroblast-Like Synoviocytes Led to Decreased ChemokineProduction
Morten Aagaard Nielsen¹, Maithri Aspari², Klaus Frommer³, Malene Hvid², Tue Kragstrup² and Bent Deleuran², ¹Aarhus University / Aarhus University Hopital, Aarhus, Denmark, ²Aarhus University, Aarhus, Denmark, ³Justus-Liebig-University Giessen, Bad Nauheim, Germany
Background/Purpose: Pathological subsets of fibroblast-like synoviocytes (FLS) have recently been identified as key players in the aggravation of both persistent joint inflammation and destruction in…
Abstract Number: 1448 • ACR Convergence 2021
Virtual Visits versus Face-to-Face Visits for Rheumatoid Arthritis (RA): Comparison of Treat to Target (TTT) Adherence in 18 US Rheumatology Practices
DH Solomon¹, Nancy Shadick¹, Theodore Pincus², Josef Smolen³, Jack Ellrodt¹, Jacklyn Stratton¹, Leah Santacroce¹, Jeffrey Katz¹, Prem Chatpar⁴, Mary Stocks⁴, Breanna Mundell⁴, Christina Downey⁵, Karina Torralba⁶, Douglas White⁷, Meggan Baudek⁷, Steven Szlembarski⁷, Sharon Barnhart⁷, Jawad Bilal⁸, Albert Redford⁸, Dylan Lee⁸, Julia Buchfuhrer⁹, Helene Kramer⁸, C. Kent Kwoh¹⁰, Michel Villatoro-Villar⁸, Asha Patnaik¹¹, Edgardo Guzman¹¹, Rebecca Trachtman¹², John Tesser¹³, Dijana Music¹⁴, Lexi Mickey¹⁵, Mona Amin¹⁶, Jeffrey Potter¹⁷, Joshua Sundhar¹⁸, Jessica Sheingold¹⁹, Juan Schmukler²⁰, Diane Horowitz²¹, Hannah Gulko²¹, Robert Quinet²², Swathi Dhulipala²³, Ronak Patel²⁴, Chandana Keshavamurthy²⁵, Guiset Carvajal Bedoya²⁶, Rhonda Dunn²⁷, Bharat Kumar²⁷, Aleksander Lenert²⁷, Hanna Zembrzuska²⁷ Matthew Gebre²⁸, Petar Lenert²⁹, Allen Anandarjah³⁰, Annie Yang³⁰, Linda Grinnell-Merrick³⁰, Shadefai Goldsmith³⁰, Jonna Zelie³⁰, Leanna Wise³¹, Nicole Zagelbaum Ward³² and Jeffrey Kaine³³ ¹Brigham and Women's Hospital, Boston, MA, ²Rush University Medical Center, Chicago, IL, ³University of Vienna, Vienna, Austria, ⁴Dr. Chatpar and Associates, LLC, Plainview, NY, ⁵Loma Linda University Medical Center, Redlands, CA, ⁶Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, ⁷Gundersen Health, La Crosse, WI, ⁸University of Arizona, Phoenix, AZ, ⁹University of Arizona, Pheonix, AZ, ¹⁰University of Arizona College of Medicine, Tuscon, AZ, ¹¹Stony Brook School of Medicine, Stony Brook, NY, ¹²Icahn School of Medicine at Mount Sinai, New York, NY, ¹³Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ¹⁴Arizona Arthritis and Rheumatology Associates, Glendale, AZ, ¹⁵Arthritis and Rheumatology Associates- Glendale, Glendale, AZ, ¹⁶Arthritis and Rheumatology Associates- Phoenix, Phoenix, AZ, ¹⁷Arthritis & Rheumatism Associates, Wheaton, MD, ¹⁸Arthritis Rheum & Back Disease Assoc., Voorhees, NJ, ¹⁹MedStar Georgetown University Hospital, Washington, DC, ²⁰Mount Sinai- Chicago, Chicago, IL, ²¹Northwell Health, Great Neck, NY, ²²Ochsner Health, River Ridge, LA, ²³Ochsner Clinic Foundation, River Ridge, LA, ²⁴Ochsner Health, Jefferson, LA, ²⁵Ochsner, New Orleans, LA, ²⁶University of Colorado, aurora, CO, ²⁷University of Iowa, Iowa City, IA, ²⁸Loma Linda University Medical Center, Loma Linda, CA, ²⁹University of Iowa Medical School, Iowa City, IA, ³⁰University of Rochester, Rochester, NY, ³¹LAC+USC/Keck Medicine of USC, Pasadena, CA, ³²LAC+USC Medical Center, Los Angeles, CA, ³³Cullowhee, NC
Background/Purpose: TTT is the recommended paradigm for managing RA according to major rheumatology organizations, however the literature suggests that TTT has not been widely implemented…
Abstract Number: 1646 • ACR Convergence 2021
Abnormal Cerebrovascular Biomarkers in Patients with Rheumatoid Arthritis: Results from a Prospective Study of Cognitive Aging
Maria Vassilaki¹, Cynthia Crowson², John Davis¹, Stephanie Duong¹, Aivi Nguyen¹, David Jones¹, Michelle Mielke¹, Vemuri Prashanthi¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cognitive impairment compared to the general population. This association might be due to chronic…
Abstract Number: 1664 • ACR Convergence 2021
Changes in Physical Function Were Not Associated with Clinically Important Changes in Muscle Strength or Physical Performance over Time – A Cohort Study
Rafaela Espírito Santo¹, Joshua Baker², Jordana Silva³, Lidiane Filippin⁴, Juliana Portes¹, Claiton Brenol¹, Rafael Chakr⁵ and Ricardo Xavier⁶, ¹Hospital de Clínicas de Porto Alegre, Laboratório de Doenças Autoimunes, Serviço de Reumatologia, Porto Alegre, Brazil; Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Porto Alegre, Brazil, ²University of Pennsylvania, Philadelphia, PA, ³Institute of musculoskeletal medicine, University Hospital Munster, Munster, Germany, ⁴Universidade La Salle, Canoas, Brazil, ⁵Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: The Health Assessment Questionnaire Disability Index (HAQ) is negatively associated with muscle strength by handgrip test and positively associated with physical performance by timed…
Abstract Number: 1680 • ACR Convergence 2021
Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials
Grace Wright¹, Eduardo Mysler², Yi-Hsing Chen³, Cassandra Kinch⁴, Arne Yndestad⁵, Kenneth Kwok⁶, Mary Jane Cadatal⁷, Rebecca Germino⁸ and Alexis Ogdie⁹, ¹Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Canada ULC, Kirkland, QC, Canada, ⁵Pfizer Inc, Oslo, Norway, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Manila, Philippines, ⁸Pfizer Inc, Groton, CT, ⁹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: While racial disparities in clinical outcomes for RA patients (pts) receiving bDMARDs or csDMARDs have been described,1 there remains a paucity of data on…
Abstract Number: 1696 • ACR Convergence 2021
Clinical Outcomes up to Week 48 of Ongoing Filgotinib RA Long-term Extension Trial of Biologic DMARD Inadequate Responders Initially on Filgotinib or Placebo in a Phase 3 Trial
Maya Buch¹, Tsutomu Takeuchi², Vijay Rajendran³, Jacques-Eric Gottenberg⁴, Alena Pechonkina⁵, YingMeei Tan⁶, Qi Gong⁵, Katrien Van Beneden⁷ and Roberto Caporali⁸, ¹University of Leeds, Leeds, United Kingdom, ²Div. Rheumatology, Keio University, Tokyo, Japan, ³Galapagos NV, Mechelen, Belgium, ⁴National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Gilead Sciences, Inc, San Diego, CA, ⁷Galapagos, NV, Mechelen, Belgium, ⁸Policlinico S. Matteo University, Pavia, Italy
Background/Purpose: The preferential Janus kinase-1 inhibitor filgotinib (FIL) is approved to treat RA in Europe and Japan. We assessed FIL efficacy and safety in patients…
Abstract Number: 1724 • ACR Convergence 2021
More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an Unfavorable Pregnancy Outcome: A Descriptive Analysis of the National French Healthcare Database
Anna Molto¹, Barbara Roux², Diep Tran², Aya Ajrouche², nathalie costedoat-Chalumeau³, Elisabeth Elefant⁴, Vassilis Tsatsaris⁵, Jeanne Fresson⁶, Brigitte Bader-Meunier⁷, Bruno Fautrel⁸ and Florence Tubach², ¹Rheumatology department, Cochin hospital, APHP, Paris, France, ²CEPHEPI, APHP, Paris, France, ³Inserm DR Paris 5, Paris, France, ⁴Teratogenic agents refernce center (CRAT) , Hôpital Trousseau, APHP, Paris, France, ⁵Obstetrics Department, Port Royal Maternity, Cochin Hospital, APHP, Paris, France, ⁶CHU Nancy, Nancy, France, ⁷Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, ⁸Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France
Background/Purpose: Women with chronic rheumatic inflammatory diseases (CRID, i.e. rheumatoid arthritis (RA) or spondyloarthritis (SpA)) have been reported to have poorer pregnancy outcomes than the…
Abstract Number: 1940 • ACR Convergence 2021
Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Jeffrey Curtis¹, Kunihiro Yamaoka², Yi-Hsing Chen³, Levent M Gunay⁴, Naonobu Sugiyama⁵, Carol A Connell⁶, Cunshan Wang⁶, Joseph Wu⁶, Sujatha Menon⁶, Ivana Vranic⁷ and Juan J Gomez-Reino⁸, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²School of Medicine, Department of Rheumatology and Infectious Diseases, Kitasato University, Sagamihara, Japan, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Inc, Istanbul, Turkey, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Tadworth, Surrey, United Kingdom, ⁸Hospital Clínico Universitario, Santiago de Compostela, Spain
Background/Purpose: ORAL Surveillance (NCT02092467) was a post-authorization safety study to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based on observed increases in…
Abstract Number: 0026 • ACR Convergence 2021
Synovial Fibroblasts Acquire a Proinflammatory and Destructive Phenotype After Exposure to αS1-Casein (CSN1S1)
Nadine Honke¹, Tim Appel¹, Matthias Schneider² and Georg Pongratz³, ¹Department of Rheumatology, Hiller Research Center Rheumatology, University Hospital Düsseldorf, Germany (* contributed equally), Düsseldorf, Germany, ²Policlinic & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, ³Polyclinic and Functional Area for Rheumatology & Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: The milk protein αS1-Casein (CSN1S1) was described to be overexpressed in synovial tissue of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Recently we…
Abstract Number: 0042 • ACR Convergence 2021
High-throughput Testing for Modified-protein Antibodies in Patients Diagnosed with “Seronegative” Rheumatoid Arthritis
Michael Richter¹, Hari Krishnamurthy², Sylvia Posso³, Jeffrey Carlin⁴ and Jane Buckner³, ¹University of Washington, Mercer Island, WA, ²Vibrant Sciences, San Carlos, CA, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Virginia Mason Medical Center, Seattle, WA
Background/Purpose: Antibodies to citrullinated and other modified proteins play a critical role in the pathogenesis of rheumatoid arthritis (RA). The prevalence and degree of multi-site…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.